Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Atacicept in Multiple Sclerosis Extension Study, Phase II
NCT00853762 · EMD Serono · PHASE2 · terminated · last registry update 2017-03-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS \[Please refer to ATAMS\]” | – | Registry record, EMD Serono |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF13B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-01-16Results posted on the registry: Human Genome Sciences Inc., a GSK Company, belimumab (NCT00712933)
- 2017-10-26Results posted on the registry: EMD Serono, Atacicept 75 milligram (mg) + Atacicept 150 mg (NCT01972568)
- 2017-10-18Phase 3 first posted: GlaxoSmithKline, Belimumab + Rituximab (NCT03312907)
- 2017-07-25Results posted on the registry: Human Genome Sciences Inc., a GSK Company, Placebo + Belimumab 200 mg SC (NCT01484496)
- 2017-06-12Also stopped (terminated): University of Pennsylvania, Belimumab (NCT01025193)
- 2017-05-30Results posted on the registry: GlaxoSmithKline, a drug against TNFSF13B (NCT02124798)
- 2017-05-23Also stopped (terminated): Anthera Pharmaceuticals, Blisibimod + Placebo (NCT02514967)
- 2017-04-28Results posted on the registry: Human Genome Sciences Inc., a GSK Company, Belimumab (NCT00583362)
- 2017-04-25Results posted on the registry: GlaxoSmithKline, Belimumab + Placebo (NCT01536379)
- 2017-03-22Also stopped (withdrawn): GlaxoSmithKline, Belimumab 10 mg + Placebo (NCT01762852)
- 2017-02-28Results posted on the registry: University of Pennsylvania, Belimumab (NCT01025193)
- 2016-12-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, Rituximab + Atacicept (NCT00664521)
- 2016-12-02Results posted on the registry: GlaxoSmithKline, Belimumab + Placebo (NCT01345253)
- 2016-07-25Results posted on the registry: Human Genome Sciences Inc., a GSK Company, Belimumab plus Early Vaccination + Belimumab plus Late Vaccination (NCT01597492)
- 2016-05-24Results posted on the registry: EMD Serono, Atacicept + Atacicept (NCT00642902)
- 2016-05-24Also stopped (terminated): EMD Serono, Atacicept + Atacicept (NCT00642902)
- 2016-04-27Results posted on the registry: GlaxoSmithKline, Belimumab (NCT01480596)
- 2016-03-28Results posted on the registry: Human Genome Sciences Inc., a GSK Company, Belimumab 1 mg/kg + Belimumab 10 mg/kg (NCT00724867)
- 2016-03-23Results posted on the registry: EMD Serono, Atacicept + Mycophenolate mofetil (NCT00573157)
- 2016-03-23Also stopped (terminated): EMD Serono, Atacicept + Mycophenolate mofetil (NCT00573157)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision